Stock Evaluator: China Shineway Pharmaceutical Group Limited (CSWYY)
China Shineway Pharmaceutical Group Limited CSWYY
$21.49
0.00
0.00%
September 22, 2026 9:30:17 AM
EST
Volume: 0
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
| DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Pharmaceuticals |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
China Shineway Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and trade of Chinese pharmaceutical products in the People’s Republic of China and Hong Kong. The company offers Chinese medicines in the form of injection, soft capsules, and granules; and other dosage forms, including pills and tablets; and traditional Chinese medicine granules in various therapeutic areas, including respiratory system disease, nervous system, digestive system disease, cardiovascular and cerebrovascular, orthopedics, pediatrics, chronic illnesses, and other areas, as well as medication for strengthening the body. It is also involved in the trading of agricultural products. The company was incorporated in 2002 and is headquartered in Shijiazhuang, China. China Shineway Pharmaceutical Group Limited operates as a subsidiary of Forway Investment Limited.
Financial Summary
| Share Statistics | CSWYY | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $806.3 | $541.1 | 43% |
|
| Shares Out (Mil) | 108.0 | 42.5 | 63% |
|
| Institutional Ownership | 3.2% | 84.5% | 4% |
|
| Float (Mil) | 207.0 | 45.7 | 74% |
|
| Beta | na | 0.72 | na |
|
| Avg Daily Volume (000s) | 0 | 417 | 0% |
|
| Price Change (52-week) |
na | 61.9% | na |
|
| Growth | CSWYY | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 2.0% | 6.1% | 23% |
|
| Net Income (5yr) | 24.6% | (1.4%) | 79% |
|
| EPS (5yr) | 24.6% | 15.1% | 75 |
|
| Dividends (5yr) | 6.5% | 0.0% | 55% |
|
| Cash Flow (5yr) | na | (15.0%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | CSWYY | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $448 | $317 | 40% |
|
| Net Income (TTM) (Mil) | $136 | ($11) | 64% |
|
| EPS (TTM) | $0.180 | ($0.700) | 46% |
|
| Operating Cash Flow (TTM) (Mil) | $168 | ($7) | 57% |
|
| Net Cash Flow (TTM) (Mil) | $147 | $5 | 81% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $6 | 10% |
|
| Enterprise Value (Q1) (Mil) | ($300) | $493 | 0% |
|
| Valuation | CSWYY | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.37 | na |
|
| P/E | na | 17.3 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | CSWYY | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 71.3% | 69.4% | 82% |
|
| Net Margin | 30.2% | 2.0% | 89% |
|
| ROA | 9.3% | (22.2%) | 86% |
|
| ROE | 12.5% | (22.8%) | 64% |
|
| Liabilities to Assets | 25.2% | 32.8% | 17% |
|
| F-Score | na | 3 | na |
|
China Shineway Pharmaceutical Group Limited did not pass any screens on 9/29/2026.
